Russia's results are only the second from a late-stage human trial, following on swiftly from data released on Monday by Pfizer Inc and BioNTech, which said their shot was also more than 90% effective.
The scramble comes amid news from the drug giant that the new vaccine requires storage at temperatures of minus 94 degrees Fahrenheit, which is far below the standard for other vaccines that require temperatures of between minus 36-46 degrees Fahrenheit, according to a report.
Gam-COVID-Vac, trade-name Sputnik V, was developed by the Gamaleya Research Institute of Epidemiology and Microbiology, and registered on August 11th by the Russian Health Ministry.
Russia's Sputnik V vaccine for COVID-19 has reportedly arrived in India after Dr Reddy's Laboratories got approval from the Drug Control General of India (DCGI) to conduct phase 2 and 3 human clinical trials of the vaccine. Sputnik V coronavirus vaccine is now undergoing phase III testing stage in Belarus, UAE, Venezuela, and other countries, while it is in phase II-III in India.
The vaccine, it is learnt, had already arrived in India for the trials from Russian Federation.
Washington, California, Oregon urge interstate travelers to quarantine for 14 days
Non-essential travel includes travel that is considered tourism or recreational in nature . "Safety remains our top priority". Meanwhile, Brown said in a social media video Thursday, "If we do not act immediately we will soon reach a breaking point".
The WHO, which is backing accelerated development of vaccines to stem the pandemic, has not yet prequalified any experimental vaccine nor issued an emergency use listing.
The calculation is based on the 20 confirmed COVID-19 cases split between vaccinated individuals and those who received the placebo, said Russian Direct Investment Fund (RDIF).
The vaccine is being tested in Belarus, India, Venezuela, and the UAE.
Pfizer on Monday declared that an early peek at its vaccine data suggests the shots maybe 90 per cent effective at preventing Covid-19, indicating the company is on track later this month to file an emergency use application with U.S. regulators.